Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Total Liabilities: 2019-2024

Historic Total Liabilities for Avidity Biosciences (RNA) over the last 6 years, with Dec 2024 value amounting to $138.9 million.

  • Avidity Biosciences' Total Liabilities rose 80.47% to $247.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $247.9 million, marking a year-over-year increase of 80.47%. This contributed to the annual value of $138.9 million for FY2024, which is 8.72% up from last year.
  • Per Avidity Biosciences' latest filing, its Total Liabilities stood at $138.9 million for FY2024, which was up 8.72% from $127.8 million recorded in FY2023.
  • Over the past 5 years, Avidity Biosciences' Total Liabilities peaked at $138.9 million during FY2024, and registered a low of $27.7 million during FY2020.
  • In the last 3 years, Avidity Biosciences' Total Liabilities had a median value of $127.8 million in 2023 and averaged $109.2 million.
  • Data for Avidity Biosciences' Total Liabilities shows a peak YoY surged of 110.44% (in 2023) over the last 5 years.
  • Over the past 5 years, Avidity Biosciences' Total Liabilities (Yearly) stood at $27.7 million in 2020, then soared by 66.76% to $46.1 million in 2021, then surged by 31.58% to $60.7 million in 2022, then spiked by 110.44% to $127.8 million in 2023, then climbed by 8.72% to $138.9 million in 2024.